keyword
MENU ▼
Read by QxMD icon Read
search

Nonsmall cell lung ca

keyword
https://www.readbyqxmd.com/read/28717642/lung-adenocarcinoma-patients-of-young-age-have-lower-egfr-mutation-rate-and-poorer-efficacy-of-egfr-tyrosine-kinase-inhibitors
#1
Shang-Gin Wu, Yih-Leong Chang, Chong-Jen Yu, Pan-Chyr Yang, Jin-Yuan Shih
Patients aged ≤50 years are rarely diagnosed with nonsmall cell lung cancer. We conducted a retrospective cohort study to understand the mutation status of EGFR and the efficacy of epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) treatment in young Asian patients with lung adenocarcinoma. We collected tumour specimens and malignant pleural effusions from lung adenocarcinoma patients from June 2005 to April 2014, recorded their clinical demographic data, and analysed EGFR mutations by reverse transcriptase PCR...
July 2017: ERJ Open Research
https://www.readbyqxmd.com/read/28682883/nivolumab-induced-myasthenia-gravis-in-a-patient-with-squamous-cell-lung-carcinoma-case-report
#2
Yu-Hsiu Chen, Feng-Cheng Liu, Chang-Hung Hsu, Chih-Feng Chian
RATIONALE: Nivolumab (Nivo) is an immune checkpoint inhibitor that has been used to treat advanced melanoma, nonsmall cell lung carcinoma, and renal cell carcinoma since 2015. Nivo is associated with several side effects, including hepatitis, pneumonitis, acute renal failure, endocrine disorder, and other immune-related adverse events. Here, we describe the case of a 65-year-old man with squamous cell lung carcinoma who developed myasthenia gravis (MG) after a third Nivo infusion. PATIENT CONCERNS: A 65-year-old man with advanced squamous cell lung carcinoma developed ptosis, diplopia, drop head, and general weakness 5 days after a third Nivo infusion...
July 2017: Medicine (Baltimore)
https://www.readbyqxmd.com/read/28674222/small-suitability-of-the-dlec1-mlh1-and-tusc4-mrna-expression-analysis-as-potential-prognostic-or-differentiating-markers-for-nsclc-patients-in-the-polish-population
#3
Jacek Kordiak, Karolina H Czarnecka, Dorota Pastuszak-Lewandoska, Adam Antczak, Monika Migdalska-Sęk, Ewa Nawrot, Daria Domańska-Senderowska, Justyna Kiszałkiewicz, Ewa Brzeziańska-Lasota
According to the latest data, lung cancer is one of the most common cancer worldwide, men contributing nearly 21.2% and women 8.6% of all diagnosed cancers. Late detection of tumour drastically reduces the chance for a cure. Thus, it is important to search for candidate biomarkers for screening of early stage nonsmall cell lung carcinoma (NSCLC). Tumour suppressor genes, DLEC1, TUSC4 and MLH1, localized on 3p21 are recognized to play a role in NSCLC carcinogenesis. The aim of this study was to assess the relationship between the DLEC1, TUSC4 and MLH1 mRNA expression, and clinical features of NSCLC patients, tobacco addiction, and tumour histopathological characteristics...
June 2017: Journal of Genetics
https://www.readbyqxmd.com/read/28671164/impact-of-chemotherapy-on-symptom-profile-oxidant-antioxidant-balance-and-nutritional-status-in-non-small-cell-lung-cancer
#4
Anant Mohan, Rosemary Poulose, Tarang Gupta, Kalpana Luthra, Ravindra M Pandey, Karan Madan, Vijay Hadda, Randeep Guleria
BACKGROUND: Lung cancer is associated with an oxidant-antioxidant imbalance that is implicated in tumor progression. However, the association of this imbalance on disease burden and treatment response is unclear. The effect of chemotherapy on oxidative stress, antioxidant status, and nutritional profile in patients with advanced nonsmall cell lung cancer (NSCLC) was prospectively evaluated. SUBJECTS AND METHODS: Patients with confirmed cytological/histological diagnosis of NSCLC were recruited...
July 2017: Lung India: Official Organ of Indian Chest Society
https://www.readbyqxmd.com/read/28659503/nonsmall-cell-lung-carcinoma-diagnostic-difficulties-in-small-biopsies-and-cytological-specimens-number-2-in-the-series-pathology-for-the-clinician-edited-by-peter-dorfm%C3%A3-ller-and-alberto-cavazza
#5
Lukas Bubendorf, Sylvie Lantuejoul, Adrianus J de Langen, Erik Thunnissen
The pathological and molecular classification of lung cancer has become substantially more complex over the past decade. For diagnostic purposes on small samples, additional stains are frequently required to distinguish between squamous cell carcinoma and adenocarcinoma. Subsequently, for advanced nonsquamous cell nonsmall cell lung carcinoma (NSCLC) patients, predictive analyses on epidermal growth factor receptor, anaplastic lymphoma kinase and ROS1 are required. In NSCLCs negative for these biomarkers, programmed death ligand-1 immunohistochemistry is performed...
June 30, 2017: European Respiratory Review: An Official Journal of the European Respiratory Society
https://www.readbyqxmd.com/read/28658153/bmi-1-overexpression-as-an-efficient-prognostic-marker-in-patients-with-nonsmall-cell-lung-cancer
#6
REVIEW
Xiaojun Zhang, Tian Tian, Wei Sun, Changting Liu, Xiangqun Fang
BACKGROUND: The prognostic effect of B-cell-specific Moloney leukemia virus insertion site 1 (Bmi-1) in patients with nonsmall cell lung cancer (NSCLC) remains controversial. We thus performed a meta-analysis to reveal the correlation between Bmi-1 with clinical features and overall survival (OS) in NSCLC. METHODS: Relevant studies were searched through PubMed, Embase, and Web of Science. Pooled hazard ratios (HRs) and 95% confidence intervals (CIs) as well as odds ratios (ORs) and 95% CIs were calculated by using STATA version 12...
June 2017: Medicine (Baltimore)
https://www.readbyqxmd.com/read/28656685/impacts-of-lung-and-tumor-volumes-on-lung-dosimetry-for-nonsmall-cell-lung-cancer
#7
Weijie Lei, Jing Jia, Ruifen Cao, Jing Song, Liqin Hu
The purpose of this study was to determine the impacts of lung and tumor volumes on normal lung dosimetry in three-dimensional conformal radiotherapy (3DCRT), step-and-shoot intensity-modulated radiotherapy (ssIMRT), and single full-arc volumetric-modulated arc therapy (VMAT) in treatment of nonsmall cell lung cancers (NSCLC). All plans were designed to deliver a total dose of 66 Gy in 33 fractions to PTV for the 32 NSCLC patients with various total (bilateral) lung volumes, planning target volumes (PTVs), and PTV locations...
June 28, 2017: Journal of Applied Clinical Medical Physics
https://www.readbyqxmd.com/read/28643734/the-significance-of-serum-leptin-level-in-patients-with-early-stage-nonsmall-cell-lung-cancer
#8
Fatih Karatas, Bulent Yalcin, Suleyman Sahin, Hakan Akbulut, Gungor Utkan, Ahmet Demirkazik, Fikri Icli
BACKGROUNDS: The serum leptin level (SLL) has been shown to increase in patients with nonsmall cell lung cancer (NSCLC). However, available data regarding the relation between SLL and tumor subtypes, survival, cachexia, and tumor respectability in NSCLC are still under debate. The aim of this study is to evaluate SLL in NSCLC patients with and without cachexia. MATERIALS AND METHODS: A total of 71 patients with early stage NSCLC were enrolled in this prospective study...
April 2017: Journal of Cancer Research and Therapeutics
https://www.readbyqxmd.com/read/28643733/a-prospective-randomized-controlled-study-of-cisplatin-versus-carboplatin-based-regimen-in-advanced-squamous-nonsmall-cell-lung-cancer
#9
Amr Shafik Saad, Ramy R Ghali, May Ahmed Shawki
BACKGROUND: The use of cisplatin (Cis) versus carboplatin (Carb) in the treatment of advanced nonsmall cell lung cancer (NSCLC) is controversial. The aim of the study was to compare the safety and efficacy of Cis versus Carb in squamous NSCLC. PATIENTS AND METHODS: A prospective, randomized, controlled, open-label study was conducted on advanced squamous NSCLC patients who were randomly assigned to receive Cis (40 mg/m 2 [day 1 and day 8]) or Carb (area under the curve = 5 [day 1]) combined with gemcitabine [Gem] (1000 mg/m 2 [day 1 and day 8]) of a 3-week schedule for six cycles...
April 2017: Journal of Cancer Research and Therapeutics
https://www.readbyqxmd.com/read/28631925/anticancer-activity-of-polyoxometalate-bisphosphonate-complexes-synthesis-characterization-in-vitro-and-in-vivo-results
#10
Amandine Boulmier, Xinxin Feng, Olivier Oms, Pierre Mialane, Eric Rivière, Christopher J Shin, Jiaqi Yao, Tadahiko Kubo, Taisuke Furuta, Eric Oldfield, Anne Dolbecq
We synthesized a series of polyoxometalate-bisphosphonate complexes containing Mo(VI)O6 octahedra, zoledronate, or an N-alkyl (n-C6 or n-C8) zoledronate analogue, and in two cases, Mn as a heterometal. Mo6L2 (L = Zol, ZolC6, ZolC8) and Mo4L2Mn (L = Zol, ZolC8) were characterized by using single-crystal X-ray crystallography and/or IR spectroscopy, elemental and energy dispersive X-ray analysis and (31)P NMR. We found promising activity against human nonsmall cell lung cancer (NCI-H460) cells with IC50 values for growth inhibition of ∼5 μM per bisphosphonate ligand...
June 20, 2017: Inorganic Chemistry
https://www.readbyqxmd.com/read/28628491/calcein-acetoxymethy-ester-enhances-the-antitumor-effects-of-doxorubicin-in-nonsmall-cell-lung-cancer-by-regulating-the-topbp1-p53rr-pathway
#11
Yinxiang Lv, Rongrong Liu, Shangzhi Xie, Xiaoxiao Zheng, Jiayan Mao, Ying Cai, Wei Chen
Calcein acetoxymethyl ester (calcein-AM) treatment has been reported to exert antitumor effects in certain cancer cells; however, the detailed mechanism of action of calcein-AM in cancers remains unclear, especially in nonsmall cell lung cancer (NSCLC). This study focused on the function and mechanism of action of calcein-AM in NSCLC. We used cell viability assays, western blotting, and EdU proliferation assay combined with calcein-AM treatment or siRNA interference to investigate the role of topoisomerase IIβ binding protein 1 (TopBP1) and p53 in NSCLC chemotherapy...
June 16, 2017: Anti-cancer Drugs
https://www.readbyqxmd.com/read/28620891/population-pharmacokinetic-modeling-of-olaratumab-an-anti-pdgfr%C3%AE-human-monoclonal-antibody-in-patients-with-advanced-and-or-metastatic-cancer
#12
Gary Mo, John R Baldwin, Debra Luffer-Atlas, Robert L Ilaria, Ilaria Conti, Michael Heathman, Damien M Cronier
BACKGROUND AND OBJECTIVES: Olaratumab is a recombinant human monoclonal antibody that binds to platelet-derived growth factor receptor-α (PDGFRα). In a randomized phase II study, olaratumab plus doxorubicin met its predefined primary endpoint for progression-free survival and achieved a highly significant improvement in overall survival versus doxorubicin alone in patients with advanced or metastatic soft tissue sarcoma (STS). In this study, we characterize the pharmacokinetics (PKs) of olaratumab in a cancer patient population...
June 15, 2017: Clinical Pharmacokinetics
https://www.readbyqxmd.com/read/28598227/integration-of-a-palliative-care-intervention-into-community-practice-for-lung-cancer-a-study-protocol-and-lessons-learned-with-implementation
#13
Huong Q Nguyen, Thomas Cuyegkeng, Tieu O Phung, Karisa Jahn, Tami Borneman, Mayra Macias, Nora Ruel, Betty Ferrell
BACKGROUND: A notable gap in the evidence base for outpatient palliative care (PC) for cancer is that most trials were conducted in specialized oncology or academic centers with limited translation and further evaluation in "real-world" settings. Health systems are desperate for guidance regarding the most effective and sustainable PC service models. OBJECTIVE: Describe the study protocol to evaluate the dissemination of a previously tested nurse-led PC intervention (PCI) for patients with lung cancer and their family caregiver in community-based settings, lessons learned in adapting and implementing the PCI, and implications for future dissemination-translational efforts Design: Two-group, prospective sequential, quasi-experimental design with Phase 1 (Usual care) followed by Phase 2 (Intervention) setting/subjects...
June 9, 2017: Journal of Palliative Medicine
https://www.readbyqxmd.com/read/28594473/tpgs-functionalized-polydopamine-modified-mesoporous-silica-as-drug-nanocarriers-for-enhanced-lung-cancer-chemotherapy-against-multidrug-resistance
#14
Wei Cheng, Chaoyu Liang, Lv Xu, Gan Liu, Nansha Gao, Wei Tao, Lingyan Luo, Yixiong Zuo, Xusheng Wang, Xudong Zhang, Xiaowei Zeng, Lin Mei
A nanocarrier system of d-a-tocopheryl polyethylene glycol 1000 succinate (TPGS)-functionalized polydopamine-coated mesoporous silica nanoparticles (NPs) is developed for sustainable and pH-responsive delivery of doxorubicin (DOX) as a model drug for the treatment of drug-resistant nonsmall cell lung cancer. Such nanoparticles are of desired particle size, drug loading, and drug release profile. The surface morphology, surface charge, and surface chemical properties are also successfully characterized by a series of techniques such as transmission electron microscopy (TEM), X-ray photoelectron spectroscopy (XPS), Brunauer-Emmett-Teller (BET) method, thermal gravimetric analysis (TGA), dynamic light scattering (DLS), and Fourier transform infrared spectroscopy (FTIR)...
June 8, 2017: Small
https://www.readbyqxmd.com/read/28589243/rnai-targeting-stmn-alleviates-the-resistance-to-taxol-and-collectively-contributes-to-down-regulate-the-malignancy-of-nsclc-cells-in-vitro-and-in-vivo
#15
Dan Long, Ting Yu, Xian Chen, Ying Liao, Xuechi Lin
Stathmin (STMN) plays a vital role in maintaining the malignant behavior of cancer through directly regulating microtubule dynamics equilibrium. Taxol, an effective chemotherapeutics mainly acting to promote microtubule polymerization, has been commercially applied in treating solid tumors, which results in serious drug resistance. Our study demonstrated that STMN RNA interference (RNAi) enlarged taxol-induced inhibitions in cellular proliferation, colony formation, and multidimensional spaces of cell immigration and decreased half maximal inhibitory concentration (IC50) of taxol in nonsmall cell lung cancer (NSCLC) NCI-H1299 cells; STMN RNAi and taxol jointly attenuated the expressions of extracellular regulated kinase (ERK), nuclear factor kappa B (NF-κB) and B cell lymphoma-2 (Bcl-2), but up regulated Bax expression and initiated intrinsic cell death pathway by activating caspase-3 and caspase-9, while inhibited interleukin 10 (IL-10) autocrine from cell culture supernatant and xenografted mouse serum, as well as intracellular expressions of IL-10 protein and mRNA in vitro; additionally, neutralizing IL-10 alone would incur cell apoptosis to some degree; the further study confirmed that RNAi targeting STMN promoted the sensitivity of taxol in different NSCLC cells...
June 7, 2017: Cell Biology and Toxicology
https://www.readbyqxmd.com/read/28588841/nasogastric-tube-administered-alectinib-achieved-long-term-survival-in-a-crizotinib-refractory-nonsmall-cell-lung-cancer-patient-with-a-poor-performance-status
#16
Osamu Kanai, Young Hak Kim, Koichi Nakatani, Kohei Fujita, Tadashi Mio
Alectinib shows remarkable efficacy against anaplastic lymphoma kinase (ALK)-positive nonsmall cell lung cancer (NSCLC), with minimal adverse effects. Therefore, alectinib may provide a survival benefit to ALK-positive NSCLC patients with a poor performance status. If the medication cannot be taken by mouth, the patient may be given alectinib through a nasogastric tube.
June 2017: Clinical Case Reports
https://www.readbyqxmd.com/read/28585617/-immunotherapy-for-lung-cancer
#17
Gyula Ostoros
Similarly to other malignancies, immune checkpoint inhibitor therapy is a revolutionary, effective new treatment possibility for lung cancer. In lung cancer carcinogenesis is related mainly to tobacco smoking with high somatic mutation rate and immunogenicity. The PD-1 inhibitor nivolumab and pembrolizumab and the PD-L1 inhibitor atezolizumab is a labelled indication in second line setting in advanced nonsmall cell lung cancer (NSCLC). Avelumab and durvalumab have promising activity as well. Based on the data of KEYNOTE 024 trial, pembrolizumab is approved in first line setting for cases with ≥50% PD-L1 expression...
June 6, 2017: Magyar Onkologia
https://www.readbyqxmd.com/read/28572122/chemotherapy-for-pulmonary-large-cell-neuroendocrine-carcinomas-does-the-regimen-matter
#18
Jules L Derks, Robert Jan van Suylen, Erik Thunnissen, Michael A den Bakker, Harry J Groen, Egbert F Smit, Ronald A Damhuis, Esther C van den Broek, Ernst-Jan M Speel, Anne-Marie C Dingemans
Pulmonary large cell neuroendocrine carcinoma (LCNEC) is rare. Chemotherapy for metastatic LCNEC ranges from small cell lung carcinoma (SCLC) regimens to nonsmall cell lung carcinoma (NSCLC) chemotherapy regimens. We analysed outcomes of chemotherapy treatments for LCNEC.The Netherlands Cancer Registry and Netherlands Pathology Registry (PALGA) were searched for patients with stage IV chemotherapy-treated LCNEC (2003-2012). For 207 patients, histology slides were available for pathology panel review. First-line platinum-based combined chemotherapy was clustered as "NSCLC-t", comprising gemcitabine, docetaxel, paclitaxel or vinorelbine; "NSCLC-pt", with pemetrexed treatment only; and "SCLC-t", consisting of etoposide chemotherapy...
June 2017: European Respiratory Journal: Official Journal of the European Society for Clinical Respiratory Physiology
https://www.readbyqxmd.com/read/28567503/planning-benchmark-study-for-sbrt-of-early-stage-nsclc-results-of-the-degro-working-group-stereotactic-radiotherapy
#19
Christos Moustakis, Oliver Blanck, Fatemeh Ebrahimi Tazehmahalleh, Mark Ka Heng Chan, Iris Ernst, Thomas Krieger, Marciana-Nona Duma, Markus Oechsner, Ute Ganswindt, Christian Heinz, Horst Alheit, Hilbert Blank, Ursula Nestle, Rolf Wiehle, Christine Kornhuber, Christian Ostheimer, Cordula Petersen, Gerhard Pollul, Wolfgang Baus, Georg Altenstein, Eric Beckers, Katrin Jurianz, Florian Sterzing, Matthias Kretschmer, Heinrich Seegenschmiedt, Torsten Maass, Stefan Droege, Ulrich Wolf, Juergen Schoeffler, Uwe Haverkamp, Hans Theodor Eich, Matthias Guckenberger
PURPOSE: The aim was to evaluate stereotactic body radiation therapy (SBRT) treatment planning variability for early stage nonsmall cell lung cancer (NSCLC) with respect to the published guidelines of the Stereotactic Radiotherapy Working Group of the German Society for Radiation Oncology (DEGRO). MATERIALS AND METHODS: Planning computed tomography (CT) scan and the structure sets (planning target volume, PTV; organs at risk, OARs) of 3 patients with early stage NSCLC were sent to 22 radiotherapy departments with SBRT experience: each department was asked to prepare a treatment plan according to the DEGRO guidelines...
May 31, 2017: Strahlentherapie und Onkologie: Organ der Deutschen Röntgengesellschaft ... [et Al]
https://www.readbyqxmd.com/read/28562552/plasma-rich-in-growth-factors-for-the-treatment-of-rapidly-progressing-refractory-corneal-melting-due-to-erlotinib-in-nonsmall-cell-lung-cancer
#20
Adriano Guarnieri, Belén Alfonso-Bartolozzi, Gianfranco Ciufo, Javier Moreno-Montañés, Ignacio Gil-Bazo
RATIONALE: Erlotinib, an antineoplastic agent, is indicated for the treatment of patients with advanced nonsmall cell lung cancer. Most common adverse events are manageable, although more severe ones require dose reduction or discontinuation of erlotinib treatment. PATIENT CONCERNS: We present a case of severe corneal ulcer treated with autologous plasma rich in growth factors. DIAGNOSES: A 76-year-old woman with stage IVB (cT2a N0 M1c) lung cancer under erlotinib treatment presented with rapidly progressing corneal ulcer...
June 2017: Medicine (Baltimore)
keyword
keyword
13799
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"